Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.

NCT ID: NCT05451862

Last Updated: 2025-08-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-21
• Study Completion Date: 2025-05-27

Brief Summary

166Ho-TARE is a promising modality for the treatment of HCC, given the unique characteristics of holmium, allowing careful patient selection and personalized dosimetry treatment planning. Further clinical evidence is needed to evaluate the safety and efficacy of 166Ho-TARE in the treatment of HCC patients with limited tumor burden, well preserved liver function and performance status and ineligible for liver transplantation and/or liver resection. This study will also provide further evidence on the dose-response relationship of 166Ho-TARE in (early) HCC.

Detailed Description

This is a prospective, single-arm, open-label, multicenter study with 166Ho-TARE in unresectable HCC patients with limited tumor burden and well-preserved liver function and performance status, ineligible for liver transplantation and/or liver resection. Eligibility for liver transplantation and liver resection is determined by the multidisciplinary tumor board. However, patients eligible for liver transplantation can still be included in the setting of bridge to transplant.

The study proposes to use 166Ho-TARE, including both therapeutic 166Ho-microspheres (QuiremSpheres™ Holmium-166 Microspheres) and scout 166Ho-microspheres (QuiremScout™ Holmium-166 Microspheres). All patients providing informed consent and meeting the selection criteria will be further screened using a scout dose of 166Ho-microspheres to evaluate 166Ho-TARE eligibility. Patients not eligible for selective 166Ho-TARE are considered screen failures and will not be considered as enrolled.

The primary endpoint will be assessed by blinded, independent central review, organized by an imaging core laboratory.

Conditions

Hepatocellular Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

166Ho-TARE treatment

Patients with unresectable HCC with a single nodule ≤ 8 cm or up to three nodules with a diameter of ≤ 5 cm (each). Those patients who fulfil the initial selection criteria will undergo a work-up procedure for further screening of 166Ho-TARE eligibility. If a patient is deemed eligible for 166Ho-TARE, the patient will be included in the study.

Group Type: OTHER

Holmium-166 treatment

Intervention Type: DEVICE

Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.

Holmium-166 work-up

Intervention Type: DEVICE

Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.

Interventions

Holmium-166 treatment

Implantation into hepatic tumors by delivery via the hepatic artery for the treatment of unresectable HCC liver tumors.

Intervention Type: DEVICE

Holmium-166 work-up

Evaluation of lung-shunt, extrahepatic deposition and intrahepatic distribution of intra-arterially injected microspheres for patients that are eligible for TARE treatment.

Intervention Type: DEVICE

Other Intervention Names

QuiremSpheresTM Holmium-166 Microspheres; QuiremScoutTM Holmium-166 Microspheres

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years

2. Multidisciplinary tumor board decision for locoregional treatment

3. Freely given, written informed consent

4. Patients with unresectable HCC with a single nodule ≤ 8 cm or up to three nodules with a diameter of ≤ 5 cm (each) eligible for selective radioembolization (including position changes of infusion catheters)

5. Non-cirrhotic patients or Child-Pugh A cirrhosis

6. ECOG performance status 0-1

7. Using an acceptable method of contraception throughout the study until survival follow up (for subjects of childbearing potential)

8. Adequate hematological, renal and liver function.

Adequate hematological function defined as:

• Hemoglobin ≥ 6 mmol/L (9.7 g/dL)
• WBC ≥ 3.0 x 10E9/L
• Absolute neutrophil count ≥ 1.5 x 10E9/L
• Platelet count ≥ 50,000/mm3

Adequate renal function defined as:

• Serum urea and serum creatinine < 1.5 times upper limit of normal (ULN)
• Creatinine clearance ≥ 45 ml/min

Adequate liver function defined as:

• Total bilirubin ≤ 35µmol/L (2.05 mg/dL)
• Albumin ≥ 30 g/L
• AST and ALT ≤ 5X ULN

Exclusion Criteria

1. Diffuse and/or infiltrative HCC (defined as HCC consisting of multiple tiny liver nodules spreading throughout the entire liver or entire lobe, without a dominant nodule)

2. Hypoperfused HCC (defined as a lack of tumor blush (i.e. reduced or no uptake of contrast fluid) observed on the intra-procedural CT)

3. No full, selective arterial coverage on intra-procedural CT

4. Life expectancy < 6 months

5. Child-Pugh score ≥7 points

6. Prior liver transplantation

7. Prior locoregional or systemic anti-cancer therapy for HCC and previous malignancies

8. Macrovascular invasion (defined as macrovascular invasion of the hepatic and/or portal vein main branches)

9. Extrahepatic metastases

10. Clinically significant ascites

11. Hepatic encephalopathy

12. Untreated active hepatitis B and/or C

13. Work-up imaging showing:

• Lung shunt > 30 Gy is simulated on 166Ho-scout imaging; or
• Uncorrectable extrahepatic deposition of simulated 166Ho-scout dose activity. Activity in the falciform ligament, portal lymph nodes and gallbladder is accepted; or
• Anticipated ineffective tumor targeting (< 150 Gy mean tumor simulated absorbed dose) of 166Ho-scout for each lesion; or
• Entire tumor burden not within the perfused liver volume (possible extrahepatic collateral supply of the tumor); or
• Perfused liver volume > 50% of whole liver tissue

14. Pregnant or breast-feeding

15. Current or history of cancer other than HCC, except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix

16. In the Investigator's opinion there is a reason that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study

17. Concurrently enrolled in another study, unless it is an observational non-interventional study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Terumo Europe N.V.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jens Ricke, Prof. Dr. med

Role: PRINCIPAL_INVESTIGATOR

Ludwig-Maximilian-University Munich (LMU)

Wolfgang Weber, Prof. Dr. med

Role: PRINCIPAL_INVESTIGATOR

Munich Technische Universität (TUM)

Thomas Kröncke, Prof. Dr. med

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Augsburg

Ralph Kickuth, Prof. Dr. med

Role: PRINCIPAL_INVESTIGATOR

Wuerzburg University Hospital

Karin Menhart, Dr.

Role: PRINCIPAL_INVESTIGATOR

Universitätsklinikum Regensburg

Peter Dietrich, PD. Dr. med.

Role: PRINCIPAL_INVESTIGATOR

Uniklinikum Erlangen

Locations

Universitätsklinikum Augsburg

Augsburg, , Germany

LMU Klinikum

Munich, , Germany

Countries

Germany

Other Identifiers

T142E3

Identifier Type: -

Identifier Source: org_study_id